acetylcarnitine has been researched along with Idiopathic Parkinson Disease in 8 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aging risk factor for Parkinson's disease is described in terms of specific disease markers including mitochondrial and gene dysfunctions relevant to energy metabolism." | 2.50 | Management of the aging risk factor for Parkinson's disease. ( Phillipson, OT, 2014) |
| "Creatine has been shown to be effective in several animal models of neurodegenerative diseases and currently is being evaluated in early stage trials in PD." | 2.42 | Bioenergetic approaches for neuroprotection in Parkinson's disease. ( Beal, MF, 2003) |
| "Parkinson's disease is accompanied by nonmotor symptoms including cognitive impairment, which precede the onset of motor symptoms in patients and are regulated by dopamine (DA) receptors and the mesocorticolimbic pathway." | 1.48 | Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats. ( Mishra, A; Shukla, R; Shukla, S; Singh, S; Srivastava, N, 2018) |
| "Two groups of 10 patients with Parkinson's disease received doses of either 1g acetyl-L-carnitine (ALC) per day for seven days or 2g." | 1.28 | Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson's disease. ( Brancasi, B; D'Ursi, R; Genco, S; Martino, R; Miccoli, A; Prudenzano, A; Puca, FM; Savarese, M; Scarcia, R; Specchio, LM, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Villa, RF | 1 |
| Ferrari, F | 1 |
| Gorini, A | 1 |
| Phillipson, OT | 1 |
| Singh, S | 2 |
| Mishra, A | 2 |
| Shukla, S | 2 |
| Srivastava, N | 1 |
| Shukla, R | 1 |
| Zhang, H | 1 |
| Jia, H | 1 |
| Liu, J | 2 |
| Ao, N | 1 |
| Yan, B | 1 |
| Shen, W | 1 |
| Wang, X | 1 |
| Li, X | 1 |
| Luo, C | 1 |
| Zaitone, SA | 1 |
| Abo-Elmatty, DM | 1 |
| Shaalan, AA | 1 |
| Beal, MF | 1 |
| Puca, FM | 1 |
| Genco, S | 1 |
| Specchio, LM | 1 |
| Brancasi, B | 1 |
| D'Ursi, R | 1 |
| Prudenzano, A | 1 |
| Miccoli, A | 1 |
| Scarcia, R | 1 |
| Martino, R | 1 |
| Savarese, M | 1 |
2 reviews available for acetylcarnitine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Management of the aging risk factor for Parkinson's disease.
Topics: Acetylcarnitine; Adenosine Triphosphate; Aging; alpha-Synuclein; Antioxidant Response Elements; Carb | 2014 |
Bioenergetic approaches for neuroprotection in Parkinson's disease.
Topics: Acetylcarnitine; Coenzymes; Creatine; Energy Metabolism; Free Radicals; Ginkgo biloba; Humans; Mitoc | 2003 |
6 other studies available for acetylcarnitine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
ATP-ases of synaptic plasma membranes in striatum: enzymatic systems for synapses functionality by in vivo administration of L-acetylcarnitine in relation to Parkinson's Disease.
Topics: Acetylcarnitine; Acetylcholine; Acetylcholinesterase; Animals; Ca(2+) Mg(2+)-ATPase; Calcium-Transpo | 2013 |
ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.
Topics: Acetylcarnitine; Animals; Antioxidants; Ataxia; Axons; Behavior, Animal; Brain; Cell Nucleus; Diseas | 2016 |
Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats.
Topics: Acetylcarnitine; Animals; Cell Line; Dopaminergic Neurons; Excitatory Amino Acid Transporter 2; Glio | 2018 |
Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease.
Topics: Acetylcarnitine; alpha-Synuclein; Antioxidants; Drug Synergism; Humans; Mitochondria; Oxidation-Redu | 2010 |
Acetyl-L-carnitine and α-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy.
Topics: Acetylcarnitine; Adenosine Triphosphate; Animals; Antioxidants; Dietary Supplements; Dopamine; Dopam | 2012 |
Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson's disease.
Topics: Acetylcarnitine; Adult; Aged; Carnitine; Electroencephalography; Electromyography; Female; Humans; M | 1990 |